Where does Cure Pharmaceutical Holding Corp. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cure Pharmaceutical Holding Corp. ranks #24,171 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cure Pharmaceutical Holding Corp. hold?

Cure Pharmaceutical Holding Corp. holds 11 US utility patents granted between 2015 and 2021, spanning 6 technology areas.

What is Cure Pharmaceutical Holding Corp.'s Innovation Score?

Cure Pharmaceutical Holding Corp. has an Innovation Score of 29.4 out of 100 (31st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cure Pharmaceutical Holding Corp. focus on?

Cure Pharmaceutical Holding Corp.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 9 patents, ranking #2,395 of 7,163 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Cure Pharmaceutical Holding Corp.'s patent grant rate increasing or decreasing?

Cure Pharmaceutical Holding Corp.'s recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cure Pharmaceutical Holding Corp.'s patents?

Cure Pharmaceutical Holding Corp.'s patents average 20.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cure Pharmaceutical Holding Corp. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cure Pharmaceutical Holding Corp.

USPTO PatentsView assignee record - 11 granted patents across 6 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cure ranks #24,171 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 6 technology areas.

#24,171
of 49,997 US assignees by volume: 31st percentile
by Innovation Score (29.4/100): 20.3
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24171 · US Corporation #24,171 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,171/49,997
PHOTO-FINISH Crave Innovations
CPC-NARROW A61K · 6 areas
INNOV-THIN 29.4/100
CLAIMS-DENSE 20.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Crave Innovations, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cure’s 29.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (29%) Velocity 0.0 pts (0%) Breadth 8.7 pts (29%) Claim depth 12.2 pts (41%)

Qualcomm Incorporated · highest

85
Cure Pharmaceutical… · this assignee

29
3D Lighting… · lowest

7

What this shows Cure's Innovation Score is 29.4/100 (31st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cure?

Each dot is one of Cure’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cure’s own 20.3 claims/patent is ABOVE the 16.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cure vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cure's grants concentrate

Cure Pharmaceutical Holding Corp. is a focused PatentsView assignee: 6 CPC subclasses with 81.8% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Cure sits between Crave Innovations, Inc. and D-fend Solutions AD Ltd..

Crave Innovations

11
Creative Edge Des…

11
Cree Huizhou Soli…

11
Cross Commerce Me…

11
Curevac Manufactu…

11
Cyalume

11
Cyborg

11
D-fend Solutions…

11
Cure Pharmaceutic… ◀

11

What this shows Cure holds 11 patents at rank #24,171, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cure

By rank, the assignees closest to #24,171 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Cure's primary technology class.

Cure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 31st percentile higher than 31% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cure Pharmaceutical Holding Corp. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	18.2%
2017	1	9.1%
2018	1	9.1%
2019	4	36.4%
2020	2	18.2%
2021	1	9.1%

Which technologies does Cure Pharmaceutical Holding Corp. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

B01D - Separation 4

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 2

A23P - Shaping OR Working OF Foodstuffs, NOT Fully Covered BY A Single Other Subclass 2

A23G - COCOA; Cocoa Products, e.g. CHOCOLATE; Substitutes FOR Cocoa OR Cocoa PRODUCTS; CONFECTIONERY; Chewing GUM; ICE-CREAM; Preparation Thereof 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cure Pharmaceutical Holding Corp.'s patent record in context - here's where to go next.

Cure Pharmaceutical Holding Corp.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 81.8% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #24,171 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cure Pharmaceutical Holding Corp. against Crave Innovations, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.